iBio
  • CDMO SERVICES
  • THERAPEUTICS AND VACCINES
    • Overview
    • Fibrosis
      • IBIO-100
    • COVID-19
      • IBIO-200 VLP Vaccine
      • IBIO-201 Subunit Vaccine
    • Classical Swine Fever
      • IBIO-400
    • Virus-Like Particles
    • LicKM
  • INVESTORS
  • CAREERS
Contact Us

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
Mar 12, 2018 8:30am EDT

iBio Patent Issues in China on Protein Glycosylation Modification

Mar 07, 2018 8:45am EST

iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics

Jan 05, 2018 5:00pm EST

iBio, Inc. Provides Corporate Update

Nov 30, 2017 4:15pm EST

iBio, Inc. Closes $4,500,000 Offering of Common Stock

Nov 29, 2017 9:00am EST

iBio, Inc. Prices $4,500,000 Firm Commitment Offering of Common Stock

Nov 28, 2017 5:07pm EST

iBio, Inc. Announces Proposed Public Offering of Common Stock

Nov 06, 2017 5:00pm EST

iBio, Inc. Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court

Oct 30, 2017 8:30am EDT

iBio CDMO President to Co-Chair South African Molecular Pharming Conference

Oct 16, 2017 7:15am EDT

iBio Announces Manufacturing Collaboration with Aethlon Medical

Oct 02, 2017 8:30am EDT

iBio Appoints James Abbey, Ph.D. as Vice President of Strategic Business Development

  • Previous
  • 1…
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807


979.446.0027  
info@ibioinc.com

iBio Created with Sketch.

Privacy Policy

Copyright © iBio 2021